STALICLA and Firefly Neuroscience enter Partnership Agreement for the Development of Electroencephalogram (EEG) as a Biomarker for Subgroups of Patients with ASD

STALICLA and Firefly Neuroscience enter Partnership Agreement for the Development of Electroencephalogram (EEG) as a Biomarker for Subgroups of Patients with ASD

The combination of STALICLA and Firefly Neurosciences’s machine learning platforms and know-how will further strengthen the development of precision medicine for these patients

Geneva, Switzerland27 March 2023, STALICLA SA and Firefly Neuroscience today announced a partnership to further validate EEG-based biomarkers in biologically enriched subgroups of patients with Autism Spectrum Disorder (ASD). This follows the successful completion of STALICLA’s Phase 1b clinical trial for its lead asset STP1 where EEG measurement was shown to be a powerful predictor of efficacy.

STALICLA and Firefly Neuroscience will leverage their technological platforms including the Databased Endophenotyping Patient Identification (DEPI) platform and the FDA-cleared Brain Network Analytics (BNA™) platform respectively to further advance EEG validation in two upcoming Phase 2 clinical trials, sponsored by STALICLA.

Applying BNA™ to the DEPI-driven biologically enriched subgroups of patients with ASD is expected to establish and expand EEG as a biomarker in the field of ASD. EEG measurements will reinforce the DEPI stratification capacity and prediction of treatment response in patients with a behavioral diagnosis of ASD.

STP1 is a tailored treatment candidate for ASD-Phenotype 1, the first DEPI-enriched subgroup of patients. STP1 positive target engagement was demonstrated by specific EEG signal modulation in brain areas of interest.

Lynn Durham, STALICLA’s CEO & Founder, commented: “STALICLA is thrilled to partner with Firefly Neuroscience to advance an EEG-based treatment response marker in the NDD population. STALICLA will leverage its DEPI platform and Firefly Neuroscience’s technology to reinforce its leadership in precision medicine for neurodevelopmental disorders with rapid implementation of precision EEG in our upcoming two phase 2 programs in Autism Spectrum Disorder.”

Jon Olsen, Firefly Neuroscience’s CEO, commented: “Firefly Neuroscience is excited to partner with STALICLA on the advancement of treatment for people with ASD. Using BNA™ to target sub-groups of patients for precision medicine treatment in the CNS space is a core focus for the company. The fact that BNA™ is FDA cleared and used by clinicians in the United States to support therapy decisions for people with mental disorders puts us in a very strong position to build a referral network in support of the commercialization of novel drugs and therapies for the treatment of NDD diseases.”

STALICLA has developed and validated a machine learning platform, DEPI, allowing ASD subgroup identification and precision medicine treatment candidate selection. With multiple clinical proof of concepts, DEPI has allowed for the identification of two distinct subgroups of patients with ASD and their tailored treatments STP1 and STP2. Both STP1 and STP2 are planned to enter Phase 2 clinical trials in 2023.

Firefly Neuroscience’s BNA™ platform is a patented technology that provides an objective, quantified assessment of cognition (brain function). It measures brain function and compares it to an FDA-cleared, normative, age-matched database using proprietary AI and advanced signal processing technology. Firefly Neuroscience’s AI platform (‘Fly-AI’) will help develop future biomarkers and companion diagnostics allowing for the expansion of existing pharma collaborations and partnerships to make the development of new CNS drugs more efficient.

About STALICLA
STALICLA is a precision molecular neuroscience clinical stage biotech company, advancing the first precision medicine platform (DEPI) for patients with neurodevelopmental disorders (NDDs), and neuropsychiatric disorders.
STALICLA’s unique approach is addressing the poor construct validity of behaviourally defined disorders through its unique platform integrating molecular data with human genetic information to create testable clinical hypotheses in psychiatry and neuroscience.
With multiple clinical proof of concepts, DEPI has allowed for the identification of two distinct subgroups of patients with Autism Spectrum Disorder (ASD) and their tailored treatments STP1 and STP2, both of which are planned to enter Phase 2 clinical trials in 2023. STP1 and STP2 hold a multi-billion market potential.
The DEPI platform has been validated in a clinical setting showing high specificity, sensitivity and positive predictive value in prospectively designed trials recalling ‘high’ responder patients to previously failed drug candidates.
STALICLA is currently preparing its next stage of growth to advance its pipelines and scale its platform.

For further information, please visit: https://stalicla.com/

About Firefly Neuroscience
Firefly Neuroscience leverages technical advances in computing and AI to deconstruct, analyze, and compare electroencephalograms (EEG), making them clinically useful for front-line clinicians to objectively measure, monitor, and manage brain function. Building on over a decade of research, the product has received FDA clearance and is commercially used in American clinics since mid-2022.
With BNA™, clinicians and their patients can now make informed, objective therapy and disease management decisions, track changes over time and improve therapy compliance. It takes the guesswork and subjectivity out of managing mental illnesses and cognitive disorders- as one can only effectively manage what can accurately be measured.
Firefly Neuroscience’s AI platform (‘Fly-AI’) has been built to develop future biomarkers and companion diagnostics (pharma) allowing for the expansion of existing pharma collaborations to bring new drugs to market. It has been used with leading companies such as Novartis, Takeda, and Purdue and is poised to revolutionize the required objective measurement for effective CNS drug development.

For further information, please visit: https://fireflyneuro.com

   Contacts

STALICLA SA
Lynn Durham, Founder & CEO
Lynn.durham@stalicla.com
Firefly Neuroscience
Jon Olsen, CEO
Jon.olsen@fireflyneuro.com
Media inquiries
Consilium Strategic Communications
stalicla@consilium-comms.com



STALICLA and Firefly Neuroscience enter Partnership Agreement for the Development of Electroencephalogram (EEG) as a Biomarker for Subgroups of Patients with ASD

THỦ THUẬT HAY

7 công cụ khắc phục sự cố mạng tốt nhất "cứu nguy" cho mạng nhà bạn

Bạn thường gặp các sự cố về mạng? Không thể truy cập? Bạn có cảm thấy bực bội và muốn kết nối càng sớm càng tốt? Bài viết này sẽ giúp bạn chẩn đoán các vấn đề về mạng và đưa ra các công cụ tích hợp sẵn trong Windows và

Thêm hiệu ứng và bật chế độ Dark mode khi xem video trên YouTube nhanh nhất

Một extension hỗ trợ xem video cho người dùng YouTube vừa được ra mắt vào hôm qua trên trình duyệt Chrome, đi kèm khá nhiều tính năng hay như: bỏ quảng cáo banner, xóa khoảng đen trên dưới video, thêm hiệu ứng video...

6 ứng dụng hỗ trợ để bạn có thể đạt được mục tiêu dễ dàng hơn

Với sự tiện dụng và luôn được mang theo bên mình, smartphone sẽ là công cụ hữu hiện giúp bạn đạt được những mục tiêu trong suốt 365 ngày của năm 2018.

Hướng dẫn cách sửa lỗi 503 Service Unavailable

Lỗi 503 Service Unavailable có thể xuất hiện trong mọi trình duyệt ở hệ điều hành bất kỳ, bao gồm từ Windows XP tới Windows 10, macOS, Linux…, thậm chí cả trên smartphone hay các máy tính phi truyền thống khác. Nếu

Tại sao tất cả lõi trong CPU luôn có cùng một tốc độ?

Nếu từng so sánh khi mua CPU mới, có thể bạn sẽ nhận ra rằng tất cả lõi CPU đều có cùng một tốc độ. Bài viết hôm nay sẽ cho bạn biết vì sao.

ĐÁNH GIÁ NHANH

Đánh giá laptop Dell XPS 13 9365 (2017): Sản phẩm cực kì đáng để bỏ tiền

Thêm vào đó, lần đầu tiên Dell giới thiệu công nghệ Dynamic Power Mode mới của mình trên một chiếc laptop, giúp tăng tốc độ xử lý khi bạn cần nhiều hiệu năng hơn. Và điều đó khá quan trọng, vì chiếc laptop này chỉ sử

Đánh giá chi tiết Windows Phone 8.1

Ứng dụng trợ lý ảo Cortana đã chiếm thế thượng phong trong bản update mới đây từ Windows Phone của Microsoft. Cùng Trang Công Nghệ review Windows Phone 8.1 vừa ra mắt.

Đánh giá Asus Zenfone Max Plus: Có gì đáng giá với mức 5,5 triệu

Asus Zenfone Max Plus mang ngôn ngữ thiết kế khá quen thuộc với mặt lưng bằng kim loại nguyên khối cứng cáp và các cạnh bên được bo cong mềm mại, tạo cảm giác dễ chịu hơn khi cầm nắm. Cảm biến vân tay đã được hãng dời